Page last updated: 2024-09-05

sorafenib and Cancer of Colon

sorafenib has been researched along with Cancer of Colon in 17 studies

Research

Studies (17)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	5 (29.41)	29.6817
2010's	11 (64.71)	24.3611
2020's	1 (5.88)	2.80

Authors

Authors	Studies
Adeniji-Popoola, O; Blagg, J; Blaukat, A; Box, G; Clarke, PA; Court, W; Czodrowski, P; Dale, T; de Haven Brandon, A; Eccles, SA; Esdar, C; Ewan, K; Fraser, E; Gowan, S; Mallinger, A; Musil, D; Ortiz-Ruiz, MJ; Poeschke, O; Raynaud, F; Rohdich, F; Samant, RS; Schiemann, K; Schneider, K; Schneider, R; Schwarz, D; Stubbs, M; TePoele, R; Valenti, M; Waalboer, D; Wienke, D; Workman, P	1
Feng, Q; Jia, J; Song, Q; Wang, L; Zhang, H; Zhang, Y; Zhang, Z; Zhao, H; Zheng, C	1
Sun, H; Wang, S	1
Bao, B; Delaney, J; Groves, K; Ho, G; Kossodo, S; Morin, J; Narayanan, N; Peterson, JD; Rajopadhye, M; Tseng, JC; Zhang, J	1
Bartlett, DL; Choudry, HA; Jeong, SY; Lee, DH; Lee, YJ; Lee, YS; Oh, SC; Park, SH; Park, YS; Yu, J	1
He, K; Yu, J; Zhang, L; Zheng, X	1
Argilés, JM; Busquets, S; López-Soriano, FJ; Penna, F; Toledo, M	1
Fiskus, W; Mitsiades, N	1
Blüthgen, N; Brummer, T; Fritsche-Guenther, R; Kempa, S; Sers, C; Witzel, F	1
Dent, P; Graf, M; Grant, S; Houghton, PJ; Mitchell, C; Park, MA; Rahmani, M; Voelkel-Johnson, C; Walker, T; Yacoub, A	1
Braun, M; Buness, A; Conrad, J; Falk, CS; Krapfenbauer, U; Kuner, R; Lund, P; Mang-Fatehi, S; Poustka, A; Ruschhaupt, M; Schäfer, R; Sers, C; Stelniec, I; Sueltmann, H	1
Awada, A; Besse-Hammer, T; Brendel, E; Delesen, H; Gil, T; Hendlisz, A; Joosten, MC; Lathia, CD; Loembé, BA; Piccart-Ghebart, M; Van Hamme, J; Whenham, N	1
Budak, K; Pestalozzi, B; Weisshaupt, Ch	1
Boersma-van Ek, W; de Jong, S; de Vries, EG; Hollema, H; Kleibeuker, JH; Kruyt, FA; Pennarun, B	1
Heim, M; Hilger, RA; Scheulen, ME; Seeber, S; Sharifi, M; Strumberg, D	1
Awada, A; Brendel, E; Faghih, M; Haase, CG; Hilger, RA; Korfee, S; Richly, H; Scheulen, ME; Schleucher, N; Schwartz, B; Seeber, S; Strumberg, D; Tewes, M; Voigtmann, R; Voliotis, D	1
Di Fiore, F; Michel, P	1

Trials

2 trial(s) available for sorafenib and Cancer of Colon

Article	Year
Safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors: results of a phase 1 trial. Journal of clinical pharmacology, 2011, Volume: 51, Issue:12 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Benzenesulfonates; Capecitabine; Colonic Neoplasms; Deoxycytidine; Diarrhea; Fatigue; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib	2011
Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Feb-10, Volume: 23, Issue:5 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cohort Studies; Colonic Neoplasms; Diarrhea; Extracellular Signal-Regulated MAP Kinases; Fatigue; Female; Humans; Liver Neoplasms; Lymphocytes; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Phosphatidylethanolamine Binding Protein; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Rectal Neoplasms; Safety; Sorafenib	2005

Article

Year

Safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors: results of a phase 1 trial.

Journal of clinical pharmacology, 2011, Volume: 51, Issue:12

Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Benzenesulfonates; Capecitabine; Colonic Neoplasms; Deoxycytidine; Diarrhea; Fatigue; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib

2011

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Feb-10, Volume: 23, Issue:5

Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cohort Studies; Colonic Neoplasms; Diarrhea; Extracellular Signal-Regulated MAP Kinases; Fatigue; Female; Humans; Liver Neoplasms; Lymphocytes; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Phosphatidylethanolamine Binding Protein; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Rectal Neoplasms; Safety; Sorafenib

2005

Other Studies

15 other study(ies) available for sorafenib and Cancer of Colon

Article	Year
A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease. Nature chemical biology, 2015, Volume: 11, Issue:12 Topics: Cell Line, Tumor; Colonic Neoplasms; Cyclin-Dependent Kinase 8; Cyclin-Dependent Kinases; Humans; Models, Molecular; Molecular Probes; Molecular Structure; Protein Kinase Inhibitors; Pyridines; Spiro Compounds	2015
A Probiotic Spore-Based Oral Autonomous Nanoparticles Generator for Cancer Therapy. Advanced materials (Deerfield Beach, Fla.), 2019, Volume: 31, Issue:43 Topics: Administration, Oral; Animals; Bacillus; Biological Transport; Caco-2 Cells; Cell Line, Tumor; Colonic Neoplasms; Doxorubicin; Drug Delivery Systems; Humans; Intestinal Absorption; Mice; Nanomedicine; Nanoparticles; Probiotics; Sorafenib; Spores	2019
Transferrin receptors targeting peptide (T7 peptide) surface-modified sorafenib nanoliposomes enhance the anti-tumor effect in colorectal cancer. Pharmaceutical development and technology, 2020, Volume: 25, Issue:9 Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Collagen Type IV; Colonic Neoplasms; Drug Delivery Systems; Humans; Liposomes; Mice; Nanoparticles; Particle Size; Peptide Fragments; Receptors, Transferrin; Sorafenib	2020
Fluorescence imaging of bombesin and transferrin receptor expression is comparable to 18F-FDG PET in early detection of sorafenib-induced changes in tumor metabolism. PloS one, 2017, Volume: 12, Issue:8 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Colonic Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Fluorescent Dyes; Fluorodeoxyglucose F18; Humans; Mice, Transgenic; Molecular Imaging; Neoplasm Transplantation; Niacinamide; Optical Imaging; Phenylurea Compounds; Positron-Emission Tomography; Radiopharmaceuticals; Random Allocation; Receptors, Bombesin; Receptors, Transferrin; Sorafenib; Treatment Outcome; Tumor Burden	2017
Ferroptosis-inducing agents enhance TRAIL-induced apoptosis through upregulation of death receptor 5. Journal of cellular biochemistry, 2019, Volume: 120, Issue:1 Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Artesunate; Colonic Neoplasms; Drug Synergism; Endoplasmic Reticulum Stress; Female; Ferroptosis; Gene Knockdown Techniques; HCT116 Cells; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Piperazines; Proto-Oncogene Proteins; Receptors, TNF-Related Apoptosis-Inducing Ligand; Sorafenib; TNF-Related Apoptosis-Inducing Ligand; Transcription Factor CHOP; Tumor Burden; Tumor Suppressor Protein p53; Up-Regulation; Xenograft Model Antitumor Assays	2019
Crizotinib induces PUMA-dependent apoptosis in colon cancer cells. Molecular cancer therapeutics, 2013, Volume: 12, Issue:5 Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Colonic Neoplasms; Crizotinib; Drug Synergism; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Mice; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyrazoles; Pyridines; Quinazolines; Sorafenib; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays	2013
Distinct behaviour of sorafenib in experimental cachexia-inducing tumours: the role of STAT3. PloS one, 2014, Volume: 9, Issue:12 Topics: Animals; Antineoplastic Agents; Cachexia; Carcinoma, Lewis Lung; Colon; Colonic Neoplasms; Lung; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Muscle, Skeletal; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; STAT3 Transcription Factor; Wasting Syndrome	2014
B-Raf Inhibition in the Clinic: Present and Future. Annual review of medicine, 2016, Volume: 67 Topics: Antineoplastic Agents; Colonic Neoplasms; Drug Resistance, Neoplasm; Humans; Imidazoles; Indoles; MAP Kinase Signaling System; Melanoma; Mitogen-Activated Protein Kinase Kinases; Niacinamide; Oximes; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Sorafenib; Sulfonamides; Thyroid Neoplasms; Vemurafenib	2016
Effects of RAF inhibitors on PI3K/AKT signalling depend on mutational status of the RAS/RAF signalling axis. Oncotarget, 2016, Feb-16, Volume: 7, Issue:7 Topics: Apoptosis; Benzimidazoles; Blotting, Western; Cell Proliferation; Colonic Neoplasms; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Mutation; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Sorafenib; Tumor Cells, Cultured	2016
Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and -independent mechanisms. Molecular pharmacology, 2009, Volume: 76, Issue:2 Topics: Antigens, CD; Antineoplastic Agents; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Benzenesulfonates; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 9; Cell Line, Tumor; Colonic Neoplasms; Drug Synergism; Enzyme Activation; HCT116 Cells; Humans; Hydroxamic Acids; JNK Mitogen-Activated Protein Kinases; Membrane Proteins; Niacinamide; Oxidoreductases; Phenylurea Compounds; Pyridines; Sorafenib; Vorinostat	2009
Down-regulation of HLA Class I and NKG2D ligands through a concerted action of MAPK and DNA methyltransferases in colorectal cancer cells. International journal of cancer, 2009, Oct-01, Volume: 125, Issue:7 Topics: Antineoplastic Agents; Benzenesulfonates; Butadienes; Colonic Neoplasms; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3B; Down-Regulation; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; GPI-Linked Proteins; HCT116 Cells; HLA-A2 Antigen; Humans; Intercellular Signaling Peptides and Proteins; Killer Cells, Natural; Mitogen-Activated Protein Kinase Kinases; Mutation; Niacinamide; Nitriles; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyridines; ras Proteins; Sorafenib	2009
[Adverse effects of new oncologic therapies]. Praxis, 2011, Jul-27, Volume: 100, Issue:15 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Cetuximab; Colonic Neoplasms; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Facial Dermatoses; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib; Trastuzumab	2011
Targeting FLIP and Mcl-1 using a combination of aspirin and sorafenib sensitizes colon cancer cells to TRAIL. The Journal of pathology, 2013, Volume: 229, Issue:3 Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenoma; Antineoplastic Agents; Apoptosis; Aspirin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colonic Neoplasms; Drug Therapy, Combination; Gene Knockdown Techniques; Humans; Intestinal Mucosa; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Recombinant Proteins; Sorafenib; TNF-Related Apoptosis-Inducing Ligand; Tumor Stem Cell Assay	2013
Antitumor effect and potentiation or reduction in cytotoxic drug activity in human colon carcinoma cells by the Raf kinase inhibitor (RKI) BAY 43-9006. International journal of clinical pharmacology and therapeutics, 2003, Volume: 41, Issue:12 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma; Cell Cycle; Colonic Neoplasms; Humans; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-raf; Pyridines; Sorafenib; Tumor Cells, Cultured	2003
[News in digestive oncology]. Bulletin du cancer, 2008, Volume: 95, Issue:1 Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cardia; Colonic Neoplasms; Combined Modality Therapy; Digestive System Neoplasms; Esophageal Neoplasms; Humans; Liver Neoplasms; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib; Stomach Neoplasms	2008